"Dr Mok emphasized the durability of that protection, pointing to a plateau in brain tumor progression and the development of new brain metastases after 36 months. Ninety-six percent of patients in the lorlatinib group who had no brain metastases at baseline saw no evidence of intracranial tumor progression from 24 months onward, through 84 months. (Patients with early progression had a higher tumor mutation burden compared to long-term responders, he noted.)\n\n“The 7-year CROWN update is very impressive and further supports lorlatinib as a highly active first-line therapy for advanced ALK-positive NSCLC,” commented Dr Schoenfeld. “[T]hese are among the most durable long-term data we have seen in advanced NSCLC. The intracranial control is also particularly important, with no new intracranial progression events reported after 30 months on lorlatinib.”"